|
|
| (6 intermediate revisions by 3 users not shown) |
| Line 1: |
Line 1: |
| __NOTOC__ | | __NOTOC__ |
| {{SI}} | | {{Diaphragmatic paralysis}} |
| {{CMG}} {{AE}} Your Name | | {{CMG}} {{AE}} {{MA}} |
| | | |
| {{SK}} Synonym 1; Synonym 2; Synonym 3 | | {{SK}}Phrenic palsy, Diaphragmatic palsy, Phrenic paralysis, Diaphragmatic paresis. |
| | | |
| ==Overview== | | ==[[Diaphragmatic paralysis overview|Overview]]== |
| Most patients with unilateral diaphragmatic paralysis are asymptomatic and do not require treatment
| | |
| | ==[[Diaphragmatic paralysis historical perspective|Historical Perspective]]== |
| | |
| | ==[[Diaphragmatic paralysis classification|Classification]]== |
| | |
| | ==[[Diaphragmatic paralysis pathophysiology|Pathophysiology]]== |
| | |
| | ==[[Diaphragmatic paralysis causes|Causes]]== |
| | |
| | ==[[Diaphragmatic paralysis differential diagnosis|Differentiating Diaphragmatic paralysis from Other Diseases]]== |
| | |
| | ==[[Diaphragmatic paralysis epidemiology and demographics|Epidemiology and Demographics]]== |
| | |
| | ==[[Diaphragmatic paralysis risk factors|Risk Factors]]== |
| | |
| | ==[[Diaphragmatic paralysis screening|Screening]]== |
| | |
| | ==[[Diaphragmatic paralysis natural history, complications and prognosis|Natural History, Complications and Prognosis]]== |
|
| |
|
| ==Historical Perspective== | | ==Diagnosis== |
| *[Disease name] was first discovered by [scientist name], a [nationality + occupation], in [year] during/following [event].
| | [[Diaphragmatic paralysis diagnostic study of choice|Diagnostic study of choice]] | [[Diaphragmatic paralysis history and symptoms|History and Symptoms]] | [[Diaphragmatic paralysis physical examination|Physical Examination]] | [[Diaphragmatic paralysis laboratory findings|Laboratory Findings]] | [[Diaphragmatic paralysis electrocardiogram|Electrocardiogram]] | [[Diaphragmatic paralysis x ray|X-Ray Findings]] | [[Diaphragmatic paralysis echocardiography and ultrasound|Echocardiography and Ultrasound]] | [[Diaphragmatic paralysis CT scan|CT-Scan Findings]] | [[ Diaphragmatic paralysis MRI|MRI Findings]] | [[Diaphragmatic paralysis other imaging findings|Other Imaging Findings]] | [[ Diaphragmatic paralysis other diagnostic studies|Other Diagnostic Studies]] |
| *In [year], [gene] mutations were first identified in the pathogenesis of [disease name].
| |
| *In [year], the first [discovery] was developed by [scientist] to treat/diagnose [disease name].
| |
|
| |
| ==Classification==
| |
| *[Disease name] may be classified according to [classification method] into [number] subtypes/groups:
| |
| :*[group1]
| |
| :*[group2]
| |
| :*[group3]
| |
| *Other variants of [disease name] include [disease subtype 1], [disease subtype 2], and [disease subtype 3].
| |
| | |
| ==Pathophysiology==
| |
| * Diaphrgm is one of the most inspiratory muscle. <ref name="pmid7050712">{{cite journal |vauthors=Roussos C, Macklem PT |title=The respiratory muscles |journal=N. Engl. J. Med. |volume=307 |issue=13 |pages=786–97 |year=1982 |pmid=7050712 |doi=10.1056/NEJM198209233071304 |url=}}</ref>
| |
|
| |
|
| *The pathogenesis of [disease name] is characterized by [feature1], [feature2], and [feature3].
| | ==Treatment== |
| *The [gene name] gene/Mutation in [gene name] has been associated with the development of [disease name], involving the [molecular pathway] pathway.
| | [[Diaphragmatic paralysis medical therapy|Medical Therapy]] | [[Diaphragmatic paralysis surgery|Surgery]] | [[Diaphragmatic paralysis primary prevention|Primary Prevention]] | [[Diaphragmatic paralysis secondary prevention|Secondary Prevention]] | [[ Diaphragmatic paralysis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Diaphragmatic paralysis future or investigational therapies|Future or Investigational Therapies]] |
| *On gross pathology, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
| |
| *On microscopic histopathological analysis, [feature1], [feature2], and [feature3] are characteristic findings of [disease name].
| |
|
| |
| ==Causes== | |
| * [Disease name] may be caused by either [cause1], [cause2], or [cause3].
| |
| * [Disease name] is caused by a mutation in the [gene1], [gene2], or [gene3] gene[s].
| |
| * There are no established causes for [disease name].
| |
| | |
| ==Differentiating [disease name] from other Diseases==
| |
| *[Disease name] must be differentiated from other diseases that cause [clinical feature 1], [clinical feature 2], and [clinical feature 3], such as:
| |
| :*[Differential dx1]
| |
| :*[Differential dx2]
| |
| :*[Differential dx3]
| |
| | |
| ==Epidemiology and Demographics==
| |
| * The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
| |
| * In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].
| |
|
| |
| ===Age===
| |
| *Patients of all age groups may develop [disease name].
| |
|
| |
| *[Disease name] is more commonly observed among patients aged [age range] years old.
| |
| *[Disease name] is more commonly observed among [elderly patients/young patients/children].
| |
|
| |
| ===Gender===
| |
| *[Disease name] affects men and women equally.
| |
| | |
| *[Gender 1] are more commonly affected with [disease name] than [gender 2].
| |
| * The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.
| |
|
| |
| ===Race===
| |
| *There is no racial predilection for [disease name].
| |
|
| |
| *[Disease name] usually affects individuals of the [race 1] race.
| |
| *[Race 2] individuals are less likely to develop [disease name].
| |
|
| |
| ==Risk Factors==
| |
| *Common risk factors in the development of [disease name] are [risk factor 1], [risk factor 2], [risk factor 3], and [risk factor 4].
| |
| | |
| == Natural History, Complications and Prognosis==
| |
| *The majority of patients with [disease name] remain asymptomatic for [duration/years].
| |
| *Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
| |
| *If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
| |
| *Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
| |
| *Prognosis is generally [excellent/good/poor], and the [1/5/10year mortality/survival rate] of patients with [disease name] is approximately [#%].
| |
|
| |
| == Diagnosis ==
| |
| ===Diagnostic Criteria===
| |
| *The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:
| |
| :*[criterion 1]
| |
| :*[criterion 2]
| |
| :*[criterion 3]
| |
| :*[criterion 4]
| |
|
| |
| === Symptoms ===
| |
| *[Disease name] is usually asymptomatic.
| |
| *Symptoms of [disease name] may include the following:
| |
| :*[symptom 1]
| |
| :*[symptom 2]
| |
| :*[symptom 3]
| |
| :*[symptom 4]
| |
| :*[symptom 5]
| |
| :*[symptom 6]
| |
|
| |
| === Physical Examination ===
| |
| *Patients with [disease name] usually appear [general appearance].
| |
| *Physical examination may be remarkable for:
| |
| :*[finding 1]
| |
| :*[finding 2]
| |
| :*[finding 3]
| |
| :*[finding 4]
| |
| :*[finding 5]
| |
| :*[finding 6]
| |
|
| |
| === Laboratory Findings ===
| |
| *There are no specific laboratory findings associated with [disease name].
| |
|
| |
|
| *A [positive/negative] [test name] is diagnostic of [disease name].
| | ==Case Studies== |
| *An [elevated/reduced] concentration of [serum/blood/urinary/CSF/other] [lab test] is diagnostic of [disease name].
| | [[Diaphragmatic paralysis case study one|Case #1]] |
| *Other laboratory findings consistent with the diagnosis of [disease name] include [abnormal test 1], [abnormal test 2], and [abnormal test 3].
| |
|
| |
| ===Imaging Findings=== | |
| *There are no [imaging study] findings associated with [disease name].
| |
| | |
| *[Imaging study 1] is the imaging modality of choice for [disease name].
| |
| *On [imaging study 1], [disease name] is characterized by [finding 1], [finding 2], and [finding 3].
| |
| *[Imaging study 2] may demonstrate [finding 1], [finding 2], and [finding 3].
| |
|
| |
| === Other Diagnostic Studies ===
| |
| *[Disease name] may also be diagnosed using [diagnostic study name].
| |
| *Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].
| |
|
| |
| == Treatment ==
| |
| === Medical Therapy ===
| |
| *There is no treatment for [disease name]; the mainstay of therapy is supportive care.
| |
|
| |
| *The mainstay of therapy for [disease name] is [medical therapy 1] and [medical therapy 2].
| |
| *[Medical therapy 1] acts by [mechanism of action 1].
| |
| *Response to [medical therapy 1] can be monitored with [test/physical finding/imaging] every [frequency/duration].
| |
|
| |
| === Surgery ===
| |
| *Surgery is the mainstay of therapy for [disease name].
| |
| *[Surgical procedure] in conjunction with [chemotherapy/radiation] is the most common approach to the treatment of [disease name].
| |
| *[Surgical procedure] can only be performed for patients with [disease stage] [disease name].
| |
|
| |
| === Prevention ===
| |
| *There are no primary preventive measures available for [disease name].
| |
|
| |
| *Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
| |
|
| |
|
| *Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].
| | [[Category: (name of the system)]] |
| ==References==
| |
| {{Reflist|2}}
| |
|
| |
| [[Category:Pulmonology]] | |